Skip to main content
Premium Trial:

Request an Annual Quote

South Korea to Use Affymetrix Arrays in Large Genome-Wide Association Study

NEW YORK (GenomeWeb News) — The South Korean government will use Affymetrix’s microarray technology in a large human genome-wide association study to identify genetic causes of “lifestyle-related” complex diseases that are prevalent in the country, the firm said today.
 
The Korean Association Resource project, also known as KARE, is commissioned by Korea’s National Institute of Health and its Center for Disease Control and Prevention, Affy said.
 
The project will use Affy’s SNP Array 5.0 to generate genotypes from more than 10,000 human samples in order to discover genes that are associated with adverse drug responses or other complex disorders.
 
It “will enable us to uncover the genes associated with diseases such as metabolic syndrome that affect many individuals in Korea," said Bermseok Oh, chief of the KNIH’s Division of Structural and Functional Genomics.
 
Affy said KARE will make the information drawn from the studies available as part of a database that may be used by other researchers.
 
Affy's South Korean supplier SeouLin Bioscience will provide the microarray technology and support the KNIH, and DNA Link, an Affymetrix service provider, will run the microarray research in its high-throughput lab.
 
“The technology will provide [KNIH] with a more unbiased and comprehensive view of genetic information relating to the Korean population," said DNA Link CEO Jong-Eun Lee.
  
According to Affy, the KARE project, which will use samples from the prospective epidemiological Ansan and Ansung cohorts in Korea, is comparable to the SNP Health Association Resource project, which is also using Affymetrix technology to identify genetic variants associated with heart, lung, blood, and sleep disorders.
 
The SHARE project is currently analyzing more than 9,000 samples collected by the US National Heart, Lung and Blood Institute and Boston University for the Framingham Heart Study.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.